Revvity, Inc. (NYSE: RVTY), announced the launch of EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus infection or to determine the immune status ...
Revvity, Inc. , today announced the launch of EUROIMMUN's CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus infection or to determine the immune status against ...
WALTHAM, Mass., March 03, 2025--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced the launch of EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a ...
Revvity, Inc. (NYSE: RVTY), today announced the launch of EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback